Republican senators launched an investigation into companies manufacturing the abortion pill mifepristone, questioning their compliance with federal safety regulations. The senators, led by Sen. Bill Cassidy (R-La.), sent a letter to FDA Commissioner Dr. Marty Makary on Wednesday, requesting details on enforcement actions against illegal online sales of unapproved abortion drugs.
Core Facts & Immediate Action
- Senate Republicans launched an inquiry into mifepristone manufacturers, citing concerns over online sales without medical oversight.
- The FDA-approved makers of mifepristone are Danco Laboratories, GenBioPro, and Evita Solutions, but illegal online retailers sell unapproved versions directly to U.S. consumers.
Deeper Dive & Context
FDA’s Role and Enforcement
The senators emphasized the FDA’s mission to protect consumers and urged the agency to prioritize oversight of online mifepristone sales. They cited federal laws prohibiting the marketing of misbranded or unapproved abortion drugs.
Political and Policy Implications
The letter follows a Guttmacher Institute report indicating a slight increase in U.S. abortion rates in 2025, despite the Supreme Court’s 2022 overturning of Roe v. Wade. The senators framed their inquiry as a measure to protect women and girls from unsafe abortion drugs.
Opposing Perspectives
While the senators highlighted risks from illegal online sales, pro-abortion-rights groups argue that restricting access to mifepristone could harm reproductive healthcare access. The FDA has not yet publicly responded to the senators’ letter.